UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

The lancet oncology, 2016-12, Vol.17 (12), p.e542-e551

2016

Volltextzugriff (PDF)

Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma

Cancer treatment reviews, 2018-11, Vol.70, p.127-137

2018

Volltextzugriff (PDF)

Resistance to targeted therapy in renal-cell carcinoma

The lancet oncology, 2009-10, Vol.10 (10), p.992-1000

2009

Volltextzugriff (PDF)

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

Cancer cell, 2020-12, Vol.38 (6), p.803-817.e4

2020

Volltextzugriff (PDF)

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

International journal of radiation oncology, biology, physics, 2016-06, Vol.95 (2), p.632-646

2016

Volltextzugriff (PDF)

YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells

Developmental cell, 2019-05, Vol.49 (3), p.425-443.e9

2019

Volltextzugriff (PDF)

Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice

Gastroenterology (New York, N.Y. 1943), 2021-03, Vol.160 (4), p.1359-1372.e13

2021

Volltextzugriff (PDF)

Cancer Immunotherapy: Past Progress and Future Directions

Seminars in oncology, 2015-08, Vol.42 (4), p.518-522

2015

Volltextzugriff (PDF)

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

The lancet oncology, 2020-12, Vol.21 (12), p.1563-1573

2020

Volltextzugriff (PDF)

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

The lancet oncology, 2020-01, Vol.21 (1), p.95-104

2020

Volltextzugriff (PDF)

BRAF Mutations in Metanephric Adenoma of the Kidney

European urology, 2012-11, Vol.62 (5), p.917-922

2012

Volltextzugriff (PDF)

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

The lancet oncology, 2018-03, Vol.19 (3), p.405-415

2018

Volltextzugriff (PDF)

Immune Therapy for Kidney Cancer: A Second Dawn?

Seminars in oncology, 2013-08, Vol.40 (4), p.492-498

2013

Volltextzugriff (PDF)

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study

The lancet oncology, 2013, Vol.14 (1), p.81-87

2013

Volltextzugriff (PDF)

Dissecting the treatment-naive ecosystem of human melanoma brain metastasis

Cell, 2022-07, Vol.185 (14), p.2591-2608.e30

2022

Volltextzugriff (PDF)

Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109–116

European urology, 2023-10, Vol.84 (4), p.e96-e97

2023

Volltextzugriff (PDF)

Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial

European urology, 2021-05, Vol.79 (5), p.659-662

2021

Volltextzugriff (PDF)

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

Urologic oncology, 2013-11, Vol.31 (8), p.1788-1793

2013

Volltextzugriff (PDF)

Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors?

The lancet oncology, 2021-05, Vol.22 (5), p.593-594

2021

Volltextzugriff (PDF)

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

European urology, 2023-11, Vol.84 (5), p.449-454

2023

Volltextzugriff (PDF)

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

European urology, 2020-12, Vol.78 (6), p.783-785

2020

Volltextzugriff (PDF)

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

European urology, 2022-10, Vol.82 (4), p.427-439

2022

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Aktive Filter

KollektionSpringer Books

ThemaMelanoma - Drug Therapy

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(107)

Publikationsform

Artikel
(113)

Sprache

Englisch
(113)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Life Sciences & Biomedicine
(79)
Humans
(68)
Female
(28)
Male
(26)
Biological And Medical Sciences
(25)
Middle Aged
(23)
Oncology
(22)
Adult
(21)
Medical Sciences
(21)
Aged
(17)
Kidney Neoplasms - Drug Therapy
(16)
Carcinoma, Renal Cell - Drug Therapy
(15)
Immunotherapy
(15)
General & Internal Medicine
(14)
Kidney Neoplasms - Pathology
(12)
Renal Cell Carcinoma
(12)
Medicine, General & Internal
(11)
Patients
(11)
Immunology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma

Resistance to targeted therapy in renal-cell carcinoma

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells

Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice

Cancer Immunotherapy: Past Progress and Future Directions

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

BRAF Mutations in Metanephric Adenoma of the Kidney

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

Immune Therapy for Kidney Cancer: A Second Dawn?

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study

Dissecting the treatment-naive ecosystem of human melanoma brain metastasis

Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109–116

Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors?

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Aktive Filter

Suchergebnisse filtern